FDA issues warnings to 30 telehealth companies over marketing violations
The letters warning of false or misleading marketing claims point to a transition from the agency’s traditional complaint-driven oversight to a more proactive monitoring system.
The US Food and Drug Administration (FDA) has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
Sent on February 20 and made public in early March, the letters cite violations including claims implying compounded products are the
